Nonalcoholic steatohepatitis (NASH) can result in liver cirrhosis and hepatocellular carcinoma (HCC). Several studies have shown that some DPP-4 inhibitors alleviate hepatic steatosis or steatohepatitis in type 2 diabetic mice or rats. We investigated effect of teneligliptin, a DPP-4 inhibitor on patients of type 2 diabetes with NASH.

Methods: 64 patients between ages 18 to 80 years were selected for study. Participants were identified as type 2 Diabetes with biopsy confirmed NASH. All enrolled patients randomized into 2 main groups, on the basis of drugs prescribed to them. GROUP A (n= 34): Teneligliptin 20 mg- Once a day. GROUP B(n=30): Metformin 1000mg Once a day. Patients were analyzed for their fasting, post prandial blood glucose level along with HBA1C value as baseline and followed-up at regular interval of 12 weeks apart till 48 weeks. AST and ALT levels were measured at base line and 12 weeks interval till 48 week. Hepatic steatosis was measured by Transient Elastography (Fibroscan).

Result: As shown in Table.

Conclusion: Result of our study revealed that Teneligliptin significantly reduce serum transaminases and liver fat content (LFC) and delay progression of NASH in type 2 diabetes mellitus patients.

V.K. Gupta: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at